n-3脂肪酸补充剂在糖尿病中的作用
本研究为随机对照试验,纳入15,480例无动脉粥样硬化性心血管疾病证据的糖尿病患者,随机接受每日1克n-3脂肪酸胶囊或匹配安慰剂(橄榄油)。主要终点为首次严重血管事件(非致死性心肌梗死或卒中、短暂性脑缺血发作或血管性死亡,排除确诊的颅内出血)。平均随访7.4年(依从率76%),脂肪酸组严重血管事件发生率为8.9%,安慰剂组为9.2%(率比0.97;95%CI 0.87至1.08;P=0.55),无显著差异。结论:在该人群中,n-3脂肪酸补充剂与安慰剂相比未显著降低严重血管事件风险。
要点
- 在无动脉粥样硬化性心血管疾病证据的糖尿病患者中,每日1克n-3脂肪酸补充剂与安慰剂相比,严重血管事件风险无显著差异(率比0.97;95%CI 0.87至1.08;P=0.55)。
- 脂肪酸组严重血管事件或任何动脉血运重建的复合结局发生率为11.4%,安慰剂组为11.5%(率比1.00;95%CI 0.91至1.09)。
- 脂肪酸组全因死亡率为9.7%,安慰剂组为10.2%(率比0.95;95%CI 0.86至1.05)。
- 两组非致死性严重不良事件发生率无显著差异。
- 平均随访7.4年,依从率76%。
适用人群与场景
- 糖尿病患者,无动脉粥样硬化性心血管疾病证据。
处置流程与药物剂量
- n-3脂肪酸组:每日1克胶囊(含n-3脂肪酸)。
- 安慰剂组:每日匹配安慰剂(橄榄油)胶囊。
研究设计与关键结果
- 研究类型:随机对照试验;样本量:15,480例;人群:无动脉粥样硬化性心血管疾病证据的糖尿病患者;干预:每日1克n-3脂肪酸胶囊;对照:每日匹配安慰剂(橄榄油)胶囊。
- 主要终点(首次严重血管事件):脂肪酸组689例(8.9%)vs 安慰剂组712例(9.2%),率比0.97(95%CI 0.87至1.08;P=0.55)。
- 次要终点(首次严重血管事件或任何动脉血运重建):脂肪酸组882例(11.4%)vs 安慰剂组887例(11.5%),率比1.00(95%CI 0.91至1.09)。
- 全因死亡:脂肪酸组752例(9.7%)vs 安慰剂组788例(10.2%),率比0.95(95%CI 0.86至1.05)。
- 非致死性严重不良事件发生率两组无显著差异。
- 平均随访7.4年,依从率76%。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于无动脉粥样硬化性心血管疾病证据的糖尿病患者,每日补充1克n-3脂肪酸未显著降低严重血管事件风险,原文结论不支持在该人群中以预防严重血管事件为目的常规使用n-3脂肪酸补充剂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Increased intake of n-3 fatty acids has been associated with a reduced risk of cardiovascular disease in observational studies, but this finding has not been confirmed in randomized trials. It remains unclear whether n-3 (also called omega-3) fatty acid supplementation has cardiovascular benefit in patients with diabetes mellitus.
METHODS: We randomly assigned 15,480 patients with diabetes but without evidence of atherosclerotic cardiovascular disease to receive 1-g capsules containing either n-3 fatty acids (fatty acid group) or matching placebo (olive oil) daily. The primary outcome was a first serious vascular event (i.e., nonfatal myocardial infarction or stroke, transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage). The secondary outcome was a first serious vascular event or any arterial revascularization.
RESULTS: During a mean follow-up of 7.4 years (adherence rate, 76%), a serious vascular event occurred in 689 patients (8.9%) in the fatty acid group and in 712 (9.2%) in the placebo group (rate ratio, 0.97; 95% confidence interval [CI], 0.87 to 1.08; P=0.55). The composite outcome of a serious vascular event or revascularization occurred in 882 patients (11.4%) and 887 patients (11.5%), respectively (rate ratio, 1.00; 95% CI, 0.91 to 1.09). Death from any cause occurred in 752 patients (9.7%) in the fatty acid group and in 788 (10.2%) in the placebo group (rate ratio, 0.95; 95% CI, 0.86 to 1.05). There were no significant between-group differences in the rates of nonfatal serious adverse events.
CONCLUSIONS: Among patients with diabetes without evidence of cardiovascular disease, there was no significant difference in the risk of serious vascular events between those who were assigned to receive n-3 fatty acid supplementation and those who were assigned to receive placebo. (Funded by the British Heart Foundation and others; Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
参考来源
- Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018. PMID: 30146932. doi:10.1056/NEJMoa1804989
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。